ArticleJournal of the American Heart Association2023

Correction to: Long-Term Efficacy, Safety, and Tolerability of Alirocumab in 8242 Patients Eligible for 3 to 5 Years of Placebo-Controlled Observation in the ODYSSEY OUTCOMES Trial.

No numbers read from the abstract.

Not cited yet